Introduction
============

Height alteration is an anthropometric index which could induce and affect different diseases such as heart disease and respiratory disorders ([@B1]).

According to previous prospective investigations in adults, there is significant association between height and risk of cancer ([@B1]). Recent studies demonstrated a significant relation between raised body mass index (BMI) and height with Hodgkin Lymphoma (HL) ([@B2],[@B3]). In addition, increased incidence of the osteosarcoma was seen in taller individuals and those with earlier pubertal growth spurts ([@B2], [@B3]). It is hypothesized that this may be correlated with growth-related genes which were associated with vitamin D receptor polymorphisms ([@B4]). Furthermore, height was indicated as a main feature for increased rate of shared site cancers in males. It was mentioned that

height related issues such as rate of susceptible cells and childhood growth-influencing exposures lead to this increased rate ([@B5]). The most reliable relations were noted for adulthood breast cancer in adults ([@B6]). In addition to adulthood assessments, there were few studies which investigated association between height and childhood malignancies. They presented controversial results in which at primordial diagnosis, ALL in children and adults was noted in taller patients ([@B7], [@B8]). However, some investigators didn't find significant relation between elevated height and childhood malignancy. They showed that patients with solid tumors had lower weight (for height) index versus leukemic patients ([@B9]). According to the few childhood studies and controversial results, we aimed to investigate association between height and malignancy in the patients referred to 17 Shahrivar pediatrics hospital in north of Iran.

Materials and Methods
=====================

This was an analytic cross-sectional study which included newly diagnosed children aged 14 years or less with a malignancy who admitted to pediatric oncology ward in 17 Shahrivar Children Hospital between 2000 and 2013 in Rasht, Iran. For the children less than 2 years of age recumbent height was assessed. Patients laid down on their back on a firm table and one person hold the head against the headboard with both hands. The second person gently flattened the knees and flexed the ankles of the patients to 90 degrees and brought the footboard up to the flat soles of the flexed feet. The length measurement was then read off the scale to the nearest 1/2 cm. For the patients aged over 2 years, height was measured in standing upright position with bare feet, while closed heels, buttocks, shoulders and occiput touched the stadiometer. Their heights were measured up to 200 centimeters. According to the lack of growth charts which specifically created and standardized for Iranian children and adolescents, the authors applied US NCHS charts for growth monitoring and assessed height status in pediatric population ([@B12]).

According to the previous studies, the median height and weight of the Iranian healthy children aged less than 15 years were under 20^th^ percentile of the NCHS ([@B13],[@B14]).

They recommended that for boys and girls up to 14 years, the comparison must be evaluated based on 25^th^, 50^th^ percentile heights ([@B13], [@B14]). Therefore, in this study, investigators applied their recommendation.

**Statistical Analysis**

In this study, data were reported by descriptive statistics and analyzed by Regression tests in SPSS version 19.

Results
=======

Two hundred and two patients including 78(38.6%) boys and 124(61.4%) girls were evaluated. Results showed that leukemia was the most common cause of malignancy .The frequencies of malignancies were summarized in [Table 1](#T1){ref-type="table"}.

Mean heights in children with malignancies were more than 25^th^ percentile, but less than 50^th^ percentile of the US NCHS charts, except for lymphoma, fibrosarcoma and retinoblastoma which were even less than 25^th^. However, there was no significant difference between mean heights of children with malignancies in comparisons with 25^th^ and 50^th^ percentile of US NCHS charts except for patients with Hodgkin lymphoma. The comparison of heights with normal values of 25^th^and 50^th^ percentile heights, based on age had been summarized in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. Mean heights of children with malignancies according to their sex in comparison with 25^th^ and 50^th^percentiles of US NCHS charts had been noted respectively in [Table 4](#T4){ref-type="table"}and [5](#T5){ref-type="table"}.Comparison of height median of children with malignancies with 25^th^ and 50^th^ percentile of US NCHS chart had been summarized in [Table 6](#T6){ref-type="table"}.

###### 

Frequency of different malignancies among newly diagnosed children

  Variable          Frequency         \%     Total   
  ----------------- ----------------- ------ ------- ------
  Leukemia          ALL               102    50.5    62.4
  AML               24                11.9           
  Lymphoma          HL                7      3.5     11.4
  NHL               16                7.9            
  Brain tumor       Brain tumor       12     6.0     6.0
  Neuroblastoma     Neuroblastoma     11     5.4     5.4
  RMS               RMS               9      4.5     4.5
  Wilms' Tumor      Wilms' Tumor      4      2.0     2.0
  Ewing             Ewing             8      4.0     4.0
  Fibrosarcoma      Fibrosarcoma      3      1.5     1.5
  Retinoblastoma    Retinoblastoma    3      1.5     1.5
  Germ cell tumor   Germ cell tumor   2      1.0     1.0
  Hepatoblastoma    Hepatoblastoma    1      0.5     0.5
  Total                               202    100     100

###### 

Comparison of the patient's heights with50^th^ percentile of US NCHS chart

  ---------------------------------------------------------------------------------------
  Variable          Mean of\          N          Mean of\   Mean of\   p-value    
                    Height                       SD score   SE score              
  ----------------- ----------------- ---------- ---------- ---------- ---------- -------
  Leukemia          ALL               112.9450   100        21.42168   2.14217    0.239

  NCHSS50           113.9690          100        20.69071   2.06907               

  AML               111.2292          24         26.77360   5.46514    0.274      

  NCHS 50           113.3167          24         26.34722   5.37810               

  Neuroblastoma     Neuroblastoma     105.9000   10         24.65067   7.79523    0.520

  NCHSS50           104.8200          10         25.01199   7.90949               

  Lymphoma          HL                119.5714   7          9.51940    3.59800    0.013

  NCHSS50           129.1286          7          11.90640   4.50020               

  NHL               131.3750          16         18.86399   4.71600    0.633      

  NCHSS50           130.4437          16         20.87400   5.21850               

  RMS               RMS               118.0556   9          34.82316   11.60772   0.644

  NCHsS50           119.3444          9          35.62657   11.87552              

  Wilms' Tumor      Wilms' Tumor      124.5000   4          8.96289    4.48144    0.566

  NCHSS50           126.6750          4          14.35627   7.17814               

  Brain tumor       Brain tumor       111.4545   11         23.52600   7.09336    0.271

  NCHS 50           113.5545          11         22.33797   6.73515               

  EWING             Ewing             123.0000   8          23.76672   8.40281    0.215

  NCHS 50           125.7625          8          21.14203   7.47484               

  Fibrosarcoma      Fibrosarcoma      105.6667   3          37.42103   21.60504   0.429

  NCHSS50           118.0333          3          44.85558   25.89738              

  Retinoblastoma    Retinoblastoma    85.6667    3          9.60902    5.54777    0.410

  NCHSS50           98.6333           3          12.22675   7.05912               

  Germ cell tumor   Germ cell tumor   113.5000   2          33.23402   23.50000   0.493

  NCHSS50           94.3000           2          6.64680    4.70000               
  ---------------------------------------------------------------------------------------

###### 

Comparison of the patient's heights with 25^th^ percentile of US NCHS chart

  ---------------------------------------------------------------------------------------
  Variable          Mean of\          N          Mean of\   Mean of\   p-value    
                    Height                       SD score   SE score              
  ----------------- ----------------- ---------- ---------- ---------- ---------- -------
  Leukemia          ALL               112.9450   100        21.42168   2.14217    0.01

  NCHSS25           110.6830          100        19.83860   1.98386               

  AML               111.2292          24         26.77360   5.46514    0.541      

  NCHS 25           110.0833          24         25.25275   5.15470               

  Neuroblastoma     Neuroblastoma     105.9000   10         24.65067   7.79523    0.034

  NCHSS25           101.9200          10         24.08083   7.61503               

  Lymphoma          HL                119.5714   7          9.51940    3.59800    0.074

  NCHSS 25          125.2429          7          11.46761   4.33435               

  NHL               131.3750          16         18.86399   4.71600    0.018      

  NCHSS 25          126.5000          16         20.07821   5.01955               

  RMS               RMS               118.0556   9          34.82316   11.60772   0.415

  NCHSS 25          115.8000          9          34.27751   11.42584              

  Wilms' Tumor      Wilms' Tumor      124.5000   4          8.96289    4.48144    0.646

  NCHSS 25          122.9000          4          13.80652   6.90326               

  Brain tumor       Brain tumor       112.5      11         24.47      7.09336    0.541

  NCHSS 25          113.5545          11         22.33797   6.73515               

  Ewing             Ewing             123.0000   8          23.76672   8.40281    0.661

  NCHSS 25          122.0250          8          20.30241   7.17799               

  Fibrosarcoma      Fibrosarcoma      105.6667   3          37.42103   21.60504   0.532

  NCHSS25           114.6667          3          43.19842   24.94062              

  Retinoblastoma    Retinoblastoma    85.6667    3          9.60902    5.54777    0.484

  NCHSS25           96.0667           3          11.68004   6.74347               

  Germ cell tumor   Germ cell tumor   113.5000   2          33.23402   23.50000   0.459

  NCHS              91.8500           2          6.29325    4.45000               
  ---------------------------------------------------------------------------------------

###### 

Comparison between mean and standard deviation of 25^th^ percentile height in malignancies based on sex

  --------------------------------------------------------------------
  Sex               Mean of\     N     Mean of\   Mean of\   p-value
                    Height(CM)         SD score   SE score   
  ----------------- ------------ ----- ---------- ---------- ---------
  **Female**        112.9671     76    24.21602   2.77777    0.122

  **NCHS 25**       111.3263     76    23.81339   2.73158    

  **Male**          114.9098     122   23.06987   2.08865    0.02

  **NCHS** **25**   112.9664     122   21.30008   1.92842    

  **Total**         114.1641     198   23.47441   1.66825    0.005

  **NCHS**          112.3369     198   22.25301   1.58145    
  --------------------------------------------------------------------

###### 

Comparison between mean and standard deviation of 50^th^ percentile height in malignancies based on sex

  --------------------------------------------------------------------------
  Sex                     Mean of\     N     Mean of\   Mean of\   p-value
                          Height(CM)         SD score   SE score   
  ----------------------- ------------ ----- ---------- ---------- ---------
  **Female**              112.9671     76    24.21602   2.77777    0.119

  **NCHS** **S** **50**   114.6566     76    24.74739   2.83872    

  **Male**                114.9098     122   23.06987   2.08865    0.09

  **NCHS** **S** **50**   116.3246     122   22.23636   2.01319    

  **Total**               114.1641     198   23.47441   1.66825    0.022

  **NCHS** **S** **50**   115.6843     198   23.18453   1.64765    
  --------------------------------------------------------------------------

###### 

Comparison of height median of children with malignancies with 25^th^ and 50^th^ percentile of US NCHS chart.

  -----------------------------------------------------------------
  **Variable**          **Median of**\    **SD score**   
                        **Height**                       
  --------------------- ----------------- -------------- ----------
  **Leukemia**          ALL               110.0000       21.31518

  NCHS25                109.2000          19.94018       

  NCHS50                112.4000          20.79901       

  AML                   100.0000          26.77360       

  NCHS25                105.2500          25.25275       

  NCHS 50               108.3500          26.34722       

  **Neuroblastoma**     Neuroblastoma     100.5000       24.65067

  NCHS25                98.9500           24.08083       

  NCHS50                101.8000          25.01199       

  **Lymphoma**          HL                115.0000       9.51940

  NCHS25                127.3000          11.46761       

  NCHS50                131.3000          11.90640       

  NHL                   133.0000          17.88641       

  NCHS25                133.1000          19.27019       

  NCHS50                137.3000          20.01986       

  **RMS**               RMS               129.000        34.82316

  NCHS25                127.4000          34.27751       

  NCHS50                131.5000          35.62657       

  **Wilms' Tumor**      Wilms' Tumor      121.5000       8.96289

  NCHS25                116.3000          13.80652       

  NCHS50                119.8000          14.35627       

  **Brain tumor**       Brain tumor       112.5000       24.47311

  NCHS25                104.7000          22.59480       

  NCHSS50               107.8000          23.55402       

  **EWING**             EWING             122\. 000      23.76

  NCHS 25               124.7000          20.30241       

  NCHS50                128.6000          21.14203       

  **Fibrosarcoma**      Fibrosarcoma      92.0000        37.42103

  NCHS25                123.6000          43.19842       

  NCHS50                127.5000          44.85558       

  **Retinoblastoma**    Retinoblastoma    84.0000        9.60902

  NCHS25                95.1000           11.68004       

  NCHS50                97.7000           12.22675       

  **Germ cell tumor**   Germ cell tumor   113.5000       33.23402

  NCHS25                91.8500           6.29325        

  NCHS50                94.3000           6.64680        
  -----------------------------------------------------------------

Discussion
==========

Childhood cancer occurred due to the aberrations in early developmental process. The genetic processes which can lead to childhood cancer are likely different from adulthood. At least, the carcinogenic process in children has so much shorter time ([@B2], [@B3], [@B10]). Some of the pediatric malignancies are clearly related to genetic aberrations involving insulin like growth factors such as Ewing sarcoma, Rhabdomyosarcoma, and osteosarcoma ([@B11], [@B12]).

On the other hand, insulin like growth factors involve in many aspects of normal physiology ([@B13], [@B14]), which among them~~,~~ growth is the most investigated ([@B15]). Height as an important parameter of growth is a product of many factors such as genetic, environmental, and nutritional factors. Previous studies have found a significant reduction in height of children with acute lymphoblastic leukemia ([@B16], [@B17]). But, according to our results, there was no significant relation between leukemia and height.

Based on previous studies, the median height and weight of the Iranian girls and boys aged less than 15 years were under 20^th^ percentile of the US NCHS charts ([@B18], [@B19]). In order to reduce this gap, cultural education along with the economic development is needed. ([@B18], [@B19]). Furthermore, Mohammad et al mentioned that median heights and weights of Iranian children up to 15 years of age were both below the 20th percentiles of NCHS standards; however, median heights and weights of 15-18 years participants laid on the 20^th^ and 25^th^ percentiles of NCHS, respectively. These results may suggested that the gap could be filled by nutritional and health services improvements along with the socio-economic developments ([@B19]). With the best of our knowledge, this is the first study about the correlation between height and pediatric malignancy in Iran. In this study we evaluated the height of 202 patients with different type of pediatric malignancies. We found that mean heights of children with malignancies were less than 50^th^ percentile NCHS but without significant difference (p\>0.05) except for Hodgkin lymphoma. On the other hand, mean heights of this patients were significantly (p\<0.05) more than 25^th^ percentile NCHS. In a study by Abtahi M and Mohammad K et al. they used median values of height to comapre Iranian children with NCHS charts ([@B15]). With consideration that in a normally distributed population median and mean values are the same, they found that 50^th^ percentile of healthy Iranian children less than 15 years of age laid on 20th percentiles of NCHS charts; so we can conclude that the mean height of our patients were significantly more than 50 percentile of the Iranian children~~.~~

There are few studies performed worldwide that evaluated correlation between height and pediatric malignancies. Our findings were inconsistent with Pui ***et al. who found no***significant deviation from population norms in any of the 10 malignancies' categories after proper adjustment for multiple significance testing([@B20]). But our findings ***were consistent with*** Fraumeni JF ***et al*** who ***mentioned that*** tall stature and an earlier pubertal growth spurt might be noted as important factors in the etiology of both osteosarcoma and Ewing sarcoma ([@B21]). Furthermore, IGF-1 is a responsible factor for enhancing tumor development in certain types of human cancer and non-malignant diseases like benign prostatic hyperplasia([@B22]).

It can increase cancer risk, cell proliferation and suppression of apoptosis ([@B23]). Furthermore, Insulin-like growth factor 1 (IGF1) motivates mitosis and hinders apoptosis and can be modified by IGF binding protein 3 (IGFBP)([@B24]). Therefore, decreased IGF-1 can indicate new strategies for cancer prevention. On the other hand ,the IGFBP-3/IGFBP-3R axis may present therapeutic and prognostic values for cancer therapy ([@B25], [@B26]). Therefore, it seems that assessing these factors could be beneficial. Our study has three major limitations. The relatively small sample size and unexpected cancer type distribution of our patients can be noted as two major limitations. As it was mentioned, brain tumors are in the second place of the most frequent pediatric malignancies, worldwide (about 20% of total) but it consist only six percent of our patients. In addition, the third limitation comes from the absence of a standardized nationwide growth chart for the Iranian children. Since this study is a clue, further, larger, and preferentially multicenter studies are mandatory which assess control group from the same geographical zone and with matched groups for age and sex.

Conclusion
==========

In this study, the median height of the patients at the time of diagnosis was more than 20^th^ percentile of the NCHS. There was a correlation between height and cancer among our patients, although, this correlation can be assessed by further cohort study.
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